Syros Pharmaceuticals, Inc. - common stock (SYRS) News

Syros Pharmaceuticals, Inc. - common stock (SYRS): $4.72

0.39 (-7.63%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Filter SYRS News Items

SYRS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SYRS News Highlights

  • For SYRS, its 30 day story count is now at 4.
  • Over the past 13 days, the trend for SYRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • PRE are the most mentioned tickers in articles about SYRS.

Latest SYRS News From Around the Web

Below are the latest news stories about SYROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SYRS as an investment opportunity.

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., December 19, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced today that it has priced an underwritten offering of 4,939,591 shares of common stock at an offering price of $4.42 per share, and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,242,588 shares of its common stock at an offering price of $4.419 p

Yahoo | December 19, 2023

individual investors who own 35% along with institutions invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw increase in their holdings value last week

Key Insights Syros Pharmaceuticals' significant individual investors ownership suggests that the key decisions are...

Yahoo | December 13, 2023

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Yahoo | December 7, 2023

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

CAMBRIDGE, Mass., December 06, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced strong and encouraging initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective, retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia

Yahoo | December 6, 2023

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential

If the first rule in the film “Fight Club” is to not talk about fight club, then the same rule applies to penny stocks with potential: you do not talk about these penny stocks with upside.

Josh Enomoto on InvestorPlace | December 3, 2023

Syros to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., November 21, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Management will also be available for one-on-one meetings. Details are as follows:

Yahoo | November 21, 2023

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Syros Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of Syros’ website at www.syros.com. Please be advised that today’s call is being recorded. […]

Yahoo | November 15, 2023

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

CAMBRIDGE, Mass., November 14, 2023--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2023 and provided a corporate update.

Yahoo | November 14, 2023

KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates

KALA BIO (KALA) delivered earnings and revenue surprises of -58.60% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 13, 2023

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

CAMBRIDGE, Mass., November 07, 2023--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 14, 2023 to report its third quarter 2023 financial results and provide a corporate update.

Yahoo | November 7, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!